Vertex Pharmaceuticals Inc
XHAM:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
XHAM:VX1
|
US |
|
T
|
thyssenkrupp nucera AG & Co KgaA
OTC:THYKF
|
DE |
|
CMOC Group Ltd
OTC:CMCLY
|
CN |
|
China Construction Bank Corp
OTC:CICHF
|
CN |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 490.76 EUR with a low forecast of 306.9 EUR and a high forecast of 594.34 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
490.76
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 490.76 EUR with a low forecast of 306.9 EUR and a high forecast of 594.34 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Gross Profit forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Pre-Tax Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
21%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
14%
The compound annual growth rate for Net Income over the next 8 years is 14%.
